Radioprotection of craniofacial bone growth.
In this review, the potential of pharmacologic therapy for prevention of radiation-induced bone growth inhibition is discussed. Significant radioprotection using the radioprotector Amifostine has been achieved in animal models of radiation-induced retardation of long and craniofacial bone growth. Moreover, radioprotection in vitro has been achieved in a number of cell lines, including osteoblast-like, endothelial, and fibroblastic. This evidence may support future clinical investigations of radioprotector Amifostine or similar substances for radioprotection of the growing craniofacial skeleton.
Gevorgyan
Artur
A
Division of Plastic Surgery, Hospital for Sick Children, Toronto, Canada.
La Scala
Giorgio C
GC
Neligan
Peter C
PC
Pang
Cho Y
CY
Forrest
Christopher R
CR
D004999:Amifostine / Q000378:metabolism / Q000494:pharmacology*; D000818:Animals; D001842:Bone and Bones / Q000187:drug effects / Q000528:radiation effects; D002460:Cell Line / Q000187:drug effects / Q000528:radiation effects; D005147:Facial Bones / Q000187:drug effects* / Q000254:growth & development / Q000528:radiation effects; D006128:Growth / Q000528:radiation effects; D023421:Models, Animal; D011833:Radiation Injuries, Experimental / Q000517:prevention & control; D011835:Radiation Protection / Q000379:methods*; D011837:Radiation-Protective Agents / Q000378:metabolism / Q000494:pharmacology*; D011878:Radiotherapy / Q000009:adverse effects
D011837:Radiation-Protective Agents; D004999:Amifostine